Discover the promising results of a phase 2 clinical trial evaluating the effectiveness and safety of HS-20094 in reducing HbA1c, fasting blood glucose, and body weight in patients with type 2 diabetes. Read more from the American Diabetes Association Scientific Sessions in Orlando, Florida.
New research presented at the American Diabetes Association Scientific Sessions in Orlando, Florida, reveals the significant efficacy of ecnoglutide (XW003), a novel cAMP signaling biased GLP-1 analog, in adults with type 2 diabetes mellitus and obesity in China.